GSE139070
RNA-seq analysis of human pancreas cell line SU8686 treated with DOT1L inhibitor (SGC0946) or DMSO
To understand the pathway alteration associated with DOT1L inhibition, we performed RNA-seq analysis of DOT1L inhibitor treated human pancreas cell line SU8686. We reported the changed pathways. Overall design: The SU8686 cells were treated with 20 µM SGC0946 or DMSO for 72 hr (triplicate)